Literature DB >> 21967109

CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase.

Rie Nishibaba1, Yuko Higashi, Juan Su, Tatsuhiko Furukawa, Kazuhiro Kawai, Takuro Kanekura.   

Abstract

CD147/basigin, highly expressed on the surface of malignant tumor cells including malignant melanoma (MM) cells, plays a critical role in the invasiveness and metastasis of MM. Metastasis is an orchestrated process comprised of multiple steps including adhesion and invasion. Integrin, a major adhesion molecule, co-localizes with CD147/basigin on the cell surface. Using the human MM cell line A375 that highly expresses CD147/basigin, we investigated whether CD147/basigin is involved in adhesion in association with integrin. CD147/basigin was knocked-down using siRNA targeting CD147 to elucidate the role of CD147/basigin. Cell adhesion was evaluated by adhesion assay on matrix-coated plates. The localization of integrin was inspected under a confocal microscope and the expression and phosphorylation of focal adhesion kinase (FAK), a downstream kinase of integrin, were examined by western blot analysis. Silencing of CD147/basigin in A375 cells by siRNA induced the phosphorylation of FAK at Y397. Integrin identified on the surface of parental cells was distributed in a speckled fashion in the cytoplasm of CD147 knockdown cells, resulting in morphological changes from a round to a polygonal shape with pseudopodial protrusions. Silencing of CD147/basigin in A375 cells clearly weakened their adhesiveness to collagen I and IV. Our results suggest that CD147/basigin regulates the adhesion of MM cells to extracellular matrices and of integrin β1 signaling via the phosphorylation of FAK.
© 2011 Japanese Dermatological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21967109     DOI: 10.1111/j.1346-8138.2011.01304.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

1.  EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma.

Authors:  Naohisa Futamura; Yoshihiro Nishida; Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Naoki Ishiguro
Journal:  Tumour Biol       Date:  2014-01-31

2.  EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer.

Authors:  Shaojun Zhu; Dake Chu; Yang Zhang; Xuxia Wang; Li Gong; Xiujuan Han; Li Yao; Miao Lan; Yanhong Li; Wei Zhang
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

3.  Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.

Authors:  Matthew R Zeiderman; Michael E Egger; Charles W Kimbrough; Christopher G England; Tess V Dupre; Kelly M McMasters; Lacey R McNally
Journal:  J Surg Res       Date:  2014-02-20       Impact factor: 2.192

4.  CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling.

Authors:  Binbin Yu; Yan Zhang; Kailiu Wu; Lizhen Wang; Yingying Jiang; Wantao Chen; Ming Yan
Journal:  J Cell Mol Med       Date:  2018-11-12       Impact factor: 5.310

Review 5.  Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence?

Authors:  Michal A Rahat
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.